SCHEMBL6073559

SCHEMBL6073559

CCNC(=O)Nc1nc2nc(Nc3ccc(N4CCNCC4)cc3)ncc2cc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 7/20 0.49
CCND1 P24385 7/20 0.49
CCNA2 P20248 5/20 0.49
CDK2 P24941 5/20 0.49
PDGFRB P09619 1/20 0.48
PDGFRA P16234 1/20 0.48
STAT6 P42226 2/20 0.47
STK17A Q9UEE5 2/20 0.47
SYK P43405 2/20 0.47
PTK2 Q05397 1/20 0.46
FGFR1 P11362 3/20 0.46
FGFR2 P21802 3/20 0.46
FGFR4 P22455 3/20 0.46
FGFR3 P22607 3/20 0.46
MAPK8 P45983 1/20 0.46
MAPK9 P45984 1/20 0.46
MAPK10 P53779 1/20 0.46
STK17B O94768 1/20 0.46
BRD4 O60885 2/20 0.45
JAK2 O60674 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6074196 0.90 SYK (0.55) SYKEGFR
SCHEMBL6073686 0.88 CDK4 (0.49) CDK4CCND1CCNA2CDK2PDGFRB
SCHEMBL6073488 0.85 CDK4 (0.50) CDK4CCND1CCNA2CDK2PDGFRB
SCHEMBL6073818 0.84 CDK4 (0.55) CDK4CCND1CCNA2CDK2SYK
SCHEMBL6073648 0.82 FGFR1 (0.44) CDK4CCND1CDK2FGFR1FGFR2
SCHEMBL6073792 0.81 ALK (0.53) SYKEGFR
SCHEMBL6073793 0.80 CDK4 (0.51) CDK4CCND1CCNA2CDK2PDGFRB
SCHEMBL6073860 0.80 CDK4 (0.53) CDK4CCND1CCNA2CDK2PDGFRB
SCHEMBL6073723 0.78 CDK4 (0.49) CDK4CCND1CCNA2CDK2PDGFRB
SCHEMBL6074079 0.78 SYK (0.55) SYKBRD4JAK2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US claimed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US claimed
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US disclosed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors CDK9, CDK19, CDK3 CDK4 19/4885CCND1 79/4885CCNA2 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.